<DOC>
	<DOCNO>NCT00928187</DOCNO>
	<brief_summary>Since first line antiretroviral ( ARV ) treatment largely accessible Sub-Saharian Africa country , documentation virological failure , drug resistance pattern second line treatment evaluation still consolidated setting viral load monitoring available non-B HIV subtype predominant . This trial aim evaluate efficacy tolerance 3 different second line treatment strategy : two recommend WHO combine two non-nucleoside reverse transcriptase inhibitor associate ritonavir boost protease inhibitor ( emtricitabine-tenofovir-lopinavir/ritonavir abacavir-didanosine-lopinavir/ritonavir ) ; third strategy combine emtricitabine-tenofovir-darunavir/ritonavir yet evaluate Sub-Saharian Africa . Darunavir potentially superior antiviral efficacy , good tolerance single daily administration may facilitate treatment adherence .</brief_summary>
	<brief_title>Evaluation Three Strategies Second-line Antiretroviral Treatment Africa ( Dakar - Bobo-Dioulasso - Yaoundé )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Patient age 18 year preinclusion monitor outpatient condition Documented HIV1 infection regardless clinical stage CD4 lymphocyte count Patient treatment failure firstline antiretroviral treatment combination include nonnucleoside reverse transcriptase inhibitor two nucleoside reverse transcriptase inhibitor , failure define 2 measurement ( 1 month interval ) plasma HIV RNA level &gt; 1000 copies/ml least 6 month uninterrupted treatment Adherence ( &gt; 80 % ) first line antiretroviral treatment ( questionnaire ) pre inclusion Patient agree take concomitant medication trial without inform investigator Informed consent sign later D15 For woman childbearing age : negative pregnancy test inclusion , plan pregnancy come 12 month agree use mechanical contraception ( without hormonal contraception ) study Infection HIV2 HIV1 group O N HIV1+2 Deficiency patient , make difficult , impossible , him/her take part trial understand information provide him/her Participation clinical trial Presence uncontrolled , ongoing opportunistic infection severe progressive disease Firstline treatment protease inhibitor , abacavir , tenofovir ddI Ongoing treatment rifampicin Severe hepatic insufficiency ( TP &lt; 50 % ) ALAT &gt; 3 x ULN Creatinine clearance calculate Cockcroft formula &lt; 50 ml/min Hb ≤ 8 g/dl Platelets &lt; 50,000 cells/mm3 Neutrophiles &lt; 500 cells/ mm3 Use drug prohibit context trial ( drug contraindicate SCP trial drug ) event tuberculosis malaria trial , list authorize medicine , necessary , dose adjustment antiretroviral medication provide Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Second line treatment</keyword>
	<keyword>WHO recommendation</keyword>
	<keyword>Africa</keyword>
	<keyword>Treatment strategy</keyword>
	<keyword>treatment experience</keyword>
</DOC>